Table 3 Univariate analysis for overall... | American Society of Hematology

Table 3

Univariate analysis for overall and progression-free survival and treatment-related mortality

	No.	5-y survival		5-y PFS		5-y TRM
	No.	%	P	%	P	%	P
Age, y			.87		.59		.71
Younger than 50	29	37	—	17	—	49	—
50 to 60	24	29	—	22	—	52	—
Older than 60	11	27	—	27	—	36	—
Disease stage			.01		.03		.22
CP1/CP2	30	48	—	31	—	42	—
AP/BP	34	19	—	11	—	53	—
Donor/recipient sex match			.12		.56		.02
F-M	14	0.09	—	0	—	83	—
Other	50	0.39	—	0.25	—	38	—
Donor/recipient CMV status			.22		.09		.75
Negative-negative	8	40	—	0.23	—	60	—
Others	50	24	—	0.16	—	52	—
ABO donor/recipient mismatch			.76		.68		.89
Mismatch	25	31	—	23	—	49	—
Match	39	34	—	19	—	47	—
Time until HSCT			.38		.29		.62
Less than 1 y	10	48	—	38	—	42	—
1 y or longer	53	31	—	18	—	48	—
Stem-cell source			.14		.52		.03
BM	38	29	—	21	—	58	—
PB	26	37	—	17	—	33	—
Allotype			.17		.001		.02
1 Ag MM	4	25	—	0	—	50	—
MUD	30	27	—	20	—	63	—
MRD	30	39	—	23	—	32	—
Preparative regimen			.54		.88		.51
FM	52	30	—	0.21	—	45	—
FAI	12	42	—	0.17	—	58	—
Acute GVHD			.99		.02		.17
No	35	32	—	13	—	38	—
Yes	29	33	—	30	—	60	—

	No.	5-y survival		5-y PFS		5-y TRM
	No.	%	P	%	P	%	P
Age, y			.87		.59		.71
Younger than 50	29	37	—	17	—	49	—
50 to 60	24	29	—	22	—	52	—
Older than 60	11	27	—	27	—	36	—
Disease stage			.01		.03		.22
CP1/CP2	30	48	—	31	—	42	—
AP/BP	34	19	—	11	—	53	—
Donor/recipient sex match			.12		.56		.02
F-M	14	0.09	—	0	—	83	—
Other	50	0.39	—	0.25	—	38	—
Donor/recipient CMV status			.22		.09		.75
Negative-negative	8	40	—	0.23	—	60	—
Others	50	24	—	0.16	—	52	—
ABO donor/recipient mismatch			.76		.68		.89
Mismatch	25	31	—	23	—	49	—
Match	39	34	—	19	—	47	—
Time until HSCT			.38		.29		.62
Less than 1 y	10	48	—	38	—	42	—
1 y or longer	53	31	—	18	—	48	—
Stem-cell source			.14		.52		.03
BM	38	29	—	21	—	58	—
PB	26	37	—	17	—	33	—
Allotype			.17		.001		.02
1 Ag MM	4	25	—	0	—	50	—
MUD	30	27	—	20	—	63	—
MRD	30	39	—	23	—	32	—
Preparative regimen			.54		.88		.51
FM	52	30	—	0.21	—	45	—
FAI	12	42	—	0.17	—	58	—
Acute GVHD			.99		.02		.17
No	35	32	—	13	—	38	—
Yes	29	33	—	30	—	60	—

— indicates not applicable; CP1, chronic phase 1; CP2, chronic phase 2; AP, accelerated phase; BP, best phase; F, female; M, male; BM, bone marrow; PB, peripheral blood; MUD, matched unrelated donor; MRD, matched related donor; FM, fludarabine, melphalan; FAI, fludarabine, cytarabine, idarubicin.

View Large

This Feature Is Available To Subscribers Only